06.23.21
Consumer dermatology company Dermala, Inc. has been granted US Patent No. 11,040,046 “Compositions and Methods for Treating Acne Vulgaris,” which covers using the human microbiome to treat and prevent acne.
Dermala’s patented technology uses novel, human microbiome-derived postbiotics, metabolites derived from beneficial bacteria in the human microbiome, that inhibit acne-causing C. acnes bacteria, including antibiotic-resistant clinical isolates from individuals with treatment-resistant acne. These beneficial postbiotics act synergistically when combined with other ingredients currently approved for treating acne. As a result, the combinations significantly increase the treatment efficacy without causing side effects, said the company. In addition, these microbiome-derived postbiotics correct the imbalance in the microbiome of individuals with acne and strengthen the acne-fighting bacteria present in the skin microbiome thus producing longer-lasting results naturally.
"The consumer dermatology is ripe for science-based solutions to treat common skin conditions," said Lada Rasochova, Ph.D., MBA, founder/CEO and the patent co-inventor. “Using the human microbiome to treat skin conditions associated with microbiome imbalances makes great scientific sense. We've demonstrated that we can deliver superior results by incorporating the human microbiome in a novel, unique, and unexpected way."
Dermala’s patented technology uses novel, human microbiome-derived postbiotics, metabolites derived from beneficial bacteria in the human microbiome, that inhibit acne-causing C. acnes bacteria, including antibiotic-resistant clinical isolates from individuals with treatment-resistant acne. These beneficial postbiotics act synergistically when combined with other ingredients currently approved for treating acne. As a result, the combinations significantly increase the treatment efficacy without causing side effects, said the company. In addition, these microbiome-derived postbiotics correct the imbalance in the microbiome of individuals with acne and strengthen the acne-fighting bacteria present in the skin microbiome thus producing longer-lasting results naturally.
"The consumer dermatology is ripe for science-based solutions to treat common skin conditions," said Lada Rasochova, Ph.D., MBA, founder/CEO and the patent co-inventor. “Using the human microbiome to treat skin conditions associated with microbiome imbalances makes great scientific sense. We've demonstrated that we can deliver superior results by incorporating the human microbiome in a novel, unique, and unexpected way."